{
  "pmcid": "12492532",
  "sha256": "3f3a1a6c3f52c19906a20bbb1cd38fab2aa2e8b25bcab53cd77e731cff8ea25a",
  "timestamp_utc": "2025-11-09T15:44:57.320138+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 8.58490181058496,
    "reading_ease": 49.498634052924814,
    "word_count": 359
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "A total of 320 patients undergoing elective first-time OPCABG surgery"
      },
      "Participants": {
        "score": 2,
        "evidence": "320 patients undergoing elective first-time OPCABG surgery"
      },
      "Intervention": {
        "score": 2,
        "evidence": "receiving 100 mg/day oral aspirin and 75 mg/day oral clopidogrel"
      },
      "Objective": {
        "score": 1,
        "evidence": "The association between clopidogrel metabolizer phenotype and the occurrence of POAF was investigated."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The incidences of POAF in the first week were compared"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 320 patients undergoing elective first-time OPCABG surgery and receiving 100 mg/day oral aspirin and 75 mg/day oral clopidogrel was reviewed from May 2017 to November 2023."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "NM group (CYP2C19 1*1, n = 163), IM group (CYP2C19 1*2 or 1*3 n = 112), and PM group (CYP2C19 2*2 or 2*3, n = 45)"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The incidence of POAF after OPCABG was 20.9% in the NM group, contrasting with 35.7% in the IM group (hazard ratio [HR] versus NM group, 1.843; 95% confidence interval [CI], 1.155 to 2.940; P = 0.0076) and 57.8% in the PM group ([HR] versus NM group, 3.363; 95% CI, 1.753 to 6.499; P < 0.0001)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 14,
    "max_score": 25
  }
}